Page last updated: 2024-09-05

sb 203580 and diallyl disulfide

sb 203580 has been researched along with diallyl disulfide in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(diallyl disulfide)
Trials
(diallyl disulfide)
Recent Studies (post-2010) (diallyl disulfide)
3,48941,13747416205

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
He, J; Lin, M; Ling, H; Su, Q; Tan, H; Yi, L; Zhou, J1

Other Studies

1 other study(ies) available for sb 203580 and diallyl disulfide

ArticleYear
Inhibition of ERK and activation of p38 are involved in diallyl disulfide induced apoptosis of leukemia HL-60 cells.
    Archives of pharmacal research, 2008, Volume: 31, Issue:6

    Topics: Allyl Compounds; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Cell Shape; Cell Survival; Disulfides; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Flow Cytometry; HL-60 Cells; Humans; Imidazoles; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Time Factors

2008